Related Experiment Video
Updated: Dec 10, 2025
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
11.5K
Watch and Wait in Mantle Cell Lymphoma.
1Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, 1305 York Avenue, 7th Floor, New York, NY 10065, USA.
Hematology/Oncology Clinics of North America
|August 31, 2020
Summary
Mantle cell lymphoma (MCL) is a heterogeneous cancer. Identifying patients suitable for the "watch and wait" approach is difficult due to undefined criteria, highlighting the need for risk stratification.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Mantle cell lymphoma (MCL) exhibits significant biological heterogeneity.
- Patient outcomes range from indolent to aggressive clinical courses.
- Observational data suggests safe observation periods for some MCL patients.
Purpose of the Study:
- To address the challenge of identifying suitable candidates for the "watch and wait" approach in MCL.
- To emphasize the need for well-defined selection criteria for non-intervention strategies.
- To highlight the potential for prospective studies in stratifying MCL patients based on biology and risk.
Main Methods:
- Review of observational studies on MCL patient management.
- Analysis of factors influencing clinical course heterogeneity.
- Discussion of the need for prospective stratification studies.
Main Results:
- Current selection criteria for the "watch and wait" strategy in MCL are not well-defined.
- Biological heterogeneity of MCL complicates risk stratification.
- Indolent MCL subtypes may be suitable for observation or novel frontline therapies.
Conclusions:
- Prospective studies stratifying MCL patients by biology and risk are crucial.
- Refining criteria for the "watch and wait" approach is necessary for optimal patient selection.
- Patients with indolent MCL represent a key group for frontline clinical trials.
